SCHEMBL8236352

SCHEMBL8236352

N#Cc1cccc(-c2nc(C(=O)O)sc2-c2cccc(Cl)c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.44
SLC22A12 Q96S37 1/20 0.44
ADORA1 P30542 6/20 0.43
ADORA2A P29274 6/20 0.43
ADORA2B P29275 2/20 0.43
PTGDR2 Q9Y5Y4 2/20 0.42
EIF4E P06730 1/20 0.42
F11 P03951 1/20 0.42
PIN1 Q13526 1/20 0.42
PDE4A P27815 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
CCR2 P41597 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
MAPK14 Q16539 1/20 0.41
CFTR P13569 1/20 0.40
RORB Q92753 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8236048 1.00 XDH (0.44) XDHSLC22A12ADORA1ADORA2AADORA2B
SCHEMBL8231726 0.93 XDH (0.50) XDHSLC22A12ADORA1ADORA2AADORA2B
SCHEMBL8235754 0.89 RORB (0.47) ADORA1ADORA2APIN1PDE4APDE4C
SCHEMBL8304828 0.88 PTGDR2 (0.40) ADORA1ADORA2AADORA2BPTGDR2EIF4E
SCHEMBL8309904 0.88 EIF4E (0.46) XDHSLC22A12ADORA1ADORA2APTGDR2
SCHEMBL8301477 0.88 PTGDR2 (0.44) XDHSLC22A12ADORA1ADORA2AADORA2B
SCHEMBL8238997 0.84 XDH (0.44) XDHSLC22A12ADORA1ADORA2APTGDR2
SCHEMBL8294962 0.84 PTGDR2 (0.43) ADORA1ADORA2AADORA2BPTGDR2PDE4A
SCHEMBL8285414 0.84 PTGDR2 (0.43) ADORA1ADORA2AADORA2BPTGDR2PDE4A
SCHEMBL12942053 0.80 MDM2 (0.43) ADORA1ADORA2APIN1PDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2467381-B1 SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND THIER USE FOR THE TREATMENT OF RETROVIRAL DISEASES AICURIS GMBH & CO KG (DE) 2014-04-30 EP disclosed
EP-2467381-B1 SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND THIER USE FOR THE TREATMENT OF RETROVIRAL DISEASES AICURIS GMBH & CO KG (DE) 2014-04-30 EP disclosed
US-8575357-B2 Substituted (thiazolyl-carbonyl)imidazolidinones and use thereof AICURIS GMBH & CO. KG (DE) 2013-11-05 US disclosed
US-8575357-B2 Substituted (thiazolyl-carbonyl)imidazolidinones and use thereof AICURIS GMBH & CO. KG (DE) 2013-11-05 US disclosed
US-8575357-B2 Substituted (thiazolyl-carbonyl)imidazolidinones and use thereof AICURIS GMBH & CO. KG (DE) 2013-11-05 US disclosed
US-20130045999-A1 SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2013-02-21 US disclosed
US-20130045999-A1 SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2013-02-21 US disclosed
US-20130045999-A1 SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2013-02-21 US disclosed
EP-2467381-A1 SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF FOR TREATING RETROVIRAL DISEASES AiCuris GmbH & Co. KG (DE) 2012-06-27 EP disclosed
WO-2011020822-A1 SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF FOR TREATING RETROVIRAL DISEASES AICURIS GMBH & CO. KG (DE) 2011-02-24 WO disclosed
WO-2011020822-A1 SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF FOR TREATING RETROVIRAL DISEASES AICURIS GMBH & CO. KG (DE) 2011-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045999-A1 SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF TPMT, AADAC, PAICS XDH 9/4885SLC22A12 2299/4885ADORA1 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.